{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:46Z","timestamp":1772119306897,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patients with chronic lymphocytic leukemia (CLL) are at high risk of developing severe COVID-19. The present study was undertaken to elucidate COVID-19 related morbidity and mortality in CLL patients treated with venetoclax. We present a single-center study of 108 patients with small lymphocytic lymphoma or CLL treated with venetoclax. Primary outcome was 30-day COVID-19 mortality. Secondary outcomes included COVID-19 severity and hospitalization rate. Forty-eight (44%) patients had PCR-verified SARS-COV-2 between March 2020 and January 2023. Thirty-six patients (75%) presented with asymptomatic\/mild COVID-19 and 12 (25%) with severe\/critical disease. The hospitalization rate was 46% with a 30-day mortality rate of only 4% and severe comorbidities as the primary cause of death. COVID-19 severity and mortality were similar before and during the Omicron era. High CIRS-scores (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.02) and thrombocytopenia (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01) were more frequent in patients with severe\/critical disease. In real-world data, most venetoclax treated patients presented with mild COVID-19. Hospitalization and mortality rates were low compared to data of general CLL populations. Our data indicate that venetoclax was a safe treatment option for CLL patients during the pandemic.\n                  <\/jats:p>","DOI":"10.1007\/s00277-024-05738-4","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T03:01:56Z","timestamp":1713409316000},"page":"3053-3060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study"],"prefix":"10.1007","volume":"103","author":[{"given":"Sophie","family":"Thau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Bj\u00f8rn","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Brieghel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten Kranker","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Wiese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui Chen","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars M\u00f8ller","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"5738_CR1","doi-asserted-by":"publisher","unstructured":"Scarf\u00f2 L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL, Campus et al (2020) Leukemia 34(9): 2354\u20132363. https:\/\/doi.org\/10.1038\/s41375-020-0959-x","DOI":"10.1038\/s41375-020-0959-x"},{"key":"5738_CR2","doi-asserted-by":"crossref","unstructured":"Rossi D, Shadman M, Condoluci A, Brown JR, Byrd JC, Gaidano G et al (2020) How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic Hemasphere 4(4): e432. https:\/\/doi.org\/10.1097%2FHS9.0000000000000432","DOI":"10.1097\/HS9.0000000000000432"},{"key":"5738_CR3","doi-asserted-by":"publisher","unstructured":"Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM et al (2020) Outcomes of COVID-19 in patients with CLL: a multicenter international experience blood. 136(10):1134\u20131143. https:\/\/doi.org\/10.1182\/blood.2020006965","DOI":"10.1182\/blood.2020006965"},{"key":"5738_CR4","doi-asserted-by":"publisher","unstructured":"Niemann CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, Brieghel C (2022) Patients with CLL have a lower risk of death from COVID-19 in the Omicron era blood. 140(5):445\u2013450. https:\/\/doi.org\/10.1182\/blood.2022016147","DOI":"10.1182\/blood.2022016147"},{"issue":"6","key":"5738_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/bjh.18807","volume":"201","author":"Y Bronstein","year":"2023","unstructured":"Bronstein Y, Levi S, Herishanu Y (2023) Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge. Br J Haematol 201(6):1125\u20131128. https:\/\/doi.org\/10.1111\/bjh.18807","journal-title":"Br J Haematol"},{"issue":"12","key":"5738_CR6","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1038\/s41375-021-01450-8","volume":"35","author":"T Chatzikonstantinou","year":"2021","unstructured":"Chatzikonstantinou T, Kapetanakis A, Scarf\u00f2 L, Karakatsoulis G, Allsup D, Cabrero AA et al (2021) COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus. CLL Study Leuk 35(12):3444\u20133454. https:\/\/doi.org\/10.1038\/s41375-021-01450-8","journal-title":"CLL Study Leuk"},{"key":"5738_CR7","doi-asserted-by":"publisher","unstructured":"Pu\u0142a B, Pruszczyk K, Pietrusza E, Morawska M, Piszczek W, Kalici\u0144ska E et al (2022) Outcome of SARS-CoV-2-infected Polish patients with chronic lymphocytic leukemia Cancers (Basel) 2022; 14(3): 558. https:\/\/doi.org\/10.3390\/cancers14030558","DOI":"10.3390\/cancers14030558"},{"issue":"12","key":"5738_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1159\/000452786","volume":"39","author":"O Al-Sawaf","year":"2016","unstructured":"Al-Sawaf O, Fischer K, Eichhorst B, Hallek M (2016) Targeted therapy of CLL. Oncol Res Treat 39(12):768\u2013778. https:\/\/doi.org\/10.1159\/000452786","journal-title":"Oncol Res Treat"},{"issue":"23","key":"5738_CR9","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/nejmoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M et al (2019) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions N. Engl J Med 380(23):2225\u20132236. https:\/\/doi.org\/10.1056\/nejmoa1815281","journal-title":"Engl J Med"},{"issue":"12","key":"5738_CR10","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/nejmoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S et al (2018) Venetoclax-Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378(12):1107\u20131120. https:\/\/doi.org\/10.1056\/nejmoa1713976","journal-title":"N Engl J Med"},{"issue":"19","key":"5738_CR11","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/nejmoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, F\u00fcrstenau M, von Tresckow J, Zhang C et al (2023) First-line venetoclax combinations in chronic lymphocytic leukemia N. Engl J Med 388(19):1739\u20131754. https:\/\/doi.org\/10.1056\/nejmoa2213093","journal-title":"Engl J Med"},{"key":"5738_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.exphem.2018.02.002","volume":"61","author":"J Mihalyova","year":"2018","unstructured":"Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R (2018) Venetoclax: a new wave in hematooncology. Exp Hematol 61:10\u201325. https:\/\/doi.org\/10.1016\/j.exphem.2018.02.002","journal-title":"Exp Hematol"},{"key":"5738_CR13","doi-asserted-by":"publisher","unstructured":"Chen C-C, Zhuang Z-J, Wu C-W, Tan Y-L, Huang C-H, Hsu C-Y et al (2022) Venetoclax decreases the expression of the spike protein through amino acids Q493 and S494 in SARS-CoV-2 Cells 11(12): 1924. https:\/\/doi.org\/10.3390\/cells11121924","DOI":"10.3390\/cells11121924"},{"issue":"18","key":"5738_CR14","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1182\/blood.2022019017","volume":"141","author":"T Tadmor","year":"2023","unstructured":"Tadmor T, Alapi H, Rokach L (2023) Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the. Omicron Surge Blood 141(18):2239\u20132244. https:\/\/doi.org\/10.1182\/blood.2022019017","journal-title":"Omicron Surge Blood"},{"key":"5738_CR15","doi-asserted-by":"publisher","first-page":"204062072210901","DOI":"10.1177\/20406207221090150","volume":"13","author":"PT Diamantopoulos","year":"2022","unstructured":"Diamantopoulos PT, Stafylidis C, Vlachopoulou D, Kontandreopoulou C-N, Giannakopoulou N, Vardaka M et al (2022) Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study. Ther Adv Hematol 13:20406207221090150. https:\/\/doi.org\/10.1177\/20406207221090150","journal-title":"Ther Adv Hematol"},{"key":"5738_CR16","doi-asserted-by":"publisher","unstructured":"Sch\u00f8nning K, Dessau RB, Jensen TG, Thorsen NM, Wiuff C, Nielsen L et al (2021) Electronic reporting of diagnostic laboratory test results from all healthcare sectors is a cornerstone of national preparedness and control of COVID-19 in Denmark APMIS. 129(7):438\u2013451. https:\/\/doi.org\/10.1111\/apm.13140","DOI":"10.1111\/apm.13140"},{"issue":"17","key":"5738_CR17","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1182\/bloodadvances.2022009164","volume":"7","author":"C Ujjani","year":"2023","unstructured":"Ujjani C, Gooley TA, Spurgeon SE, Stephens DM, Lai C, Broome CM et al (2023) Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia. Blood Adv 7(17):4728\u20134737. https:\/\/doi.org\/10.1182\/bloodadvances.2022009164","journal-title":"Blood Adv"},{"issue":"1","key":"5738_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ejh.13519","volume":"106","author":"A Glenth\u00f8j","year":"2021","unstructured":"Glenth\u00f8j A, Jakobsen LH, Sengel\u00f8v H, Ahmad SA, Qvist K, Rewes A et al (2021) SARS-CoV-2 infection among patients with haematological disorders: severity and one-month outcome in 66 Danish patients in a nationwide cohort study. Eur J Haematol 106(1):72\u201381. https:\/\/doi.org\/10.1111\/ejh.13519","journal-title":"Eur J Haematol"},{"issue":"4","key":"5738_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF et al (2016) Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):311\u2013322. https:\/\/doi.org\/10.1056\/nejmoa1513257","journal-title":"N Engl J Med"},{"key":"5738_CR20","doi-asserted-by":"publisher","first-page":"204993612198954","DOI":"10.1177\/2049936121989548","volume":"8","author":"I Ruiz-Camps","year":"2021","unstructured":"Ruiz-Camps I, Aguilar-Company J (2021) Risk of infection associated with targeted therapies for solid organ and hematological malignancies Ther. Adv Infec Dis 8:2049936121989548. https:\/\/doi.org\/10.1177\/2049936121989548","journal-title":"Adv Infec Dis"},{"issue":"22","key":"5738_CR21","doi-asserted-by":"publisher","first-page":"12088","DOI":"10.1080\/07391102.2021.1967786","volume":"40","author":"S Ghosh","year":"2022","unstructured":"Ghosh S, Bhattacherjee D, Satpati P, Bhabak KP (2022) Venetoclax: a promising repurposed drug against SARS-CoV-2 main protease. J Biomol Struc Dyn 40(22):12088\u201312099. https:\/\/doi.org\/10.1080\/07391102.2021.1967786","journal-title":"J Biomol Struc Dyn"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05738-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T02:05:56Z","timestamp":1722045956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05738-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["5738"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05738-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3750075\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"13 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the regional Data Protection Agency (ID: EMN-2022-11065).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was provided by patients alive at follow-up.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"CB has received honoria from Octapharma and AstraZeneca. The remaining authors have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}